본문으로 건너뛰기
저널
BMC cancer
코퍼스 내 활동 2004–2026
전체 논문 (839편 · 1/28)
-
Predicting PD-L1 expression in advanced EGFR-mutant lung adenocarcinoma patients using NECT, CECT radiomics and clinical features.
-
Immunotherapy combinations in favourable risk score metastatic renal cell carcinoma, an individual patients data metanalysis.
-
M6A modification-related genes characterize prognostic risk and immune regulation in lung adenocarcinoma.
-
Response assessment of patients with locally advanced renal cell carcinoma receiving prior systemic therapy.
-
Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: a network meta-analysis.
-
Risk signals and clinical characteristics of serious adverse events of neutropenia associated with pembrolizumab: a FAERS database study.
-
Early effects of ionizing radiation on molecular modifications and hallmarks of Immunogenic cell death in mouse tumor cells.
-
Association between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies.
-
Efficacy and safety of atezolizumab combined with bevacizumab-based chemotherapy in advanced malignancies: a systematic review and meta-analysis of randomized trials.
-
Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1).
-
Comparative study of clinical features, pathology, and immunophenotype between HIV-related cutaneous and visceral Kaposi's sarcoma.
-
Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma.
-
The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-guérin and an anti-PD-1 inhibitor in bladder cancer.
-
Clinical, diagnostic and prognostic relevance of GATA3 in malignant pleural mesothelioma: a retrospective cohort study.
-
Efficacy of PD-1 inhibitor plus induction chemotherapy for nasopharyngeal carcinoma with high-grade extranodal extension: a multicenter retrospective analysis.
-
Educational and regional differences in population-based incidence and survival of primary central nervous system lymphoma in Finland.
-
Prognostic value of diffusely increased FDG uptake in spleen and/ or bone marrow due to reticuloendothelial system activation in lymphoma patients.
-
Diagnostic value of 18 F-FDG PET-CT combined with ultrasound-guided percutaneous core needle biopsy for patients with primary gastrointestinal lymphomas: a multicenter study.
-
Correction to: Early-stage hodgkin lymphoma in Cape Town, South Africa: prognostic risk factors at diagnosis and treatment outcomes.
-
P300 enhances glycolysis and dox resistance in DLBCL by upregulating HK2 expression through histone lactylation.
-
Prognostic factors and nomogram development for adult diffuse large B-cell lymphoma: a single-center retrospective cohort study.
-
Real-world outcome and dose intensity of Pola-R-CHP versus R-CHOP/R-THP-COP in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective cohort study.
-
Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.
-
Time to haematologist visit and non-haematological referral from primary health care during blood cancer diagnosis - findings from a large national survey in Australia.
-
Adolescents' perceptions and lived experiences of cancer patient-hood: a qualitative study.
-
The prognostic value of metabolic heterogeneity parameter coefficient of variation (COV) of baseline F-FDG PET/CT in newly diagnosed diffuse large B-cell lymphoma.
-
Evaluating functional hyposplenism in pediatric hodgkin lymphoma: the role of marginal zone b cells post-radiotherapy.
-
High-risk subgroup and associated genes identified by next generation sequencing in diffuse large B cell lymphoma.
-
Real-life data of patients with chronic myeloid leukemia in Amazonas.
-
Efficacy and safety of ATRA plus arsenic trioxide versus ATRA plus chemotherapy in newly diagnosed acute promyelocytic leukemia: a grade-assessed systematic review and meta-analysis.